Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 101, Issue -, Pages 881-888Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2018.03.029
Keywords
Helicteres angustifolia L.; Polysaccharide; Immunomodulatory activity; 4T1 tumor-bearing mice
Funding
- National Natural Science Foundation of China [81602460]
Ask authors/readers for more resources
To evaluate the in vivo immunomodulatory activity of the crude polysaccharide from Helicteres angustifolia L. (HACP), a 4T1 breast tumor model in BALB/c mice was used in this study. After tumor incubation for 6 days, mice were orally administered with 100, 200, and 300 mg/kg of HACP for 15 days. The results show that HACP administration resulted in a remarkable immunomodulatory effect attributable to the increased spleen and thymus indices, unregulated CD4(+)/CD8(+) ratios in spleen lymphocytes, and the augmentation of IL-1 beta, IFN-gamma, and TNF-alpha productions in the serum of tumor-bearing mice. The increased immunity resulted in a significant reduction in the tumor weight in 100, 200, and 300 mg/kg of HACP treatment groups, achieving inhibition rates of 34.58 +/- 10.20%, 57.80 +/- 8.65% and 67.71 +/- 5.80%, respectively. In addition, a reduced lung metastasis was also detected in the HACP treatment groups. These findings, for the first time, provide scientific evidence that HACP can improve the immune response in 4T1 tumor-bearing mice, which plays a major role in the antitumor effect. Thus, HACP is prospectively valuable to be developed as new products with immunomodulatory activity and used for the treatment of breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available